Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy.
Document Type
Article
Publication Date
3-1-2021
Publication Title
Case Reports in Nephrology
Abstract
A 65-year-old male patient with metastatic CCRCC developed steroid-dependent, grade 3 AIN secondary to nivolumab weeks after its initiation that resulted in 3 hospitalizations with acute renal failure. The patient was started on MM and his AIN was successfully controlled after a 2-year period of follow-up. Refractory renal AIN resulting from PD-1 inhibitor use is rare, and its successful treatment with mofetil mycophenolate with a 2-year follow-up in a patient with metastatic CCRCC has not been reported. This case is important because not only was his renal irAEs controlled but also long-term treatment with MM did not result in progression of metastatic disease.
Volume
2021
First Page
6640154
Last Page
6640154
Recommended Citation
Faieta A, Dancik T. Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy. Case Rep Nephrol. 2021 Mar 1;2021:6640154. doi: 10.1155/2021/6640154. PMID: 33728076; PMCID: PMC7939740.
DOI
10.1155/2021/6640154
ISSN
2090-6641
PubMed ID
33728076